Consistent findings with NOAC plus aspirin in CAD and PAD with and without diabetes - PACE-CME

Consistent findings with NOAC plus aspirin in CAD and PAD with and without diabetes

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

One step closer to controlling LDL-c levels in HoFH with PCSK9i
One step closer to controlling LDL-c levels in HoFH with PCSK9i
ACC 2020
One step closer to controlling LDL-c levels in HoFH with PCSK9i
- Dirk Blom, PhD
Use of ARNI in HFpEF patients reduces NT-proBNP levels
Use of ARNI in HFpEF patients reduces NT-proBNP levels
ACC 2020
Use of ARNI in HFpEF patients reduces NT-proBNP levels
- Jonathan Cunningham, MD
Mechanistic underpinning of CV benefit observed with icosapent ethyl
Mechanistic underpinning of CV benefit observed with icosapent ethyl
ACC 2020
Mechanistic underpinning of CV benefit observed with icosapent ethyl
- Deepak Bhatt, MD
Remarkable reduction of LDL-c with antibody against angiopoietin-like protein 3 in HoFH
Remarkable reduction of LDL-c with antibody against angiopoietin-like protein 3 in HoFH
ACC 2020
Remarkable reduction of LDL-c with antibody against angiopoietin-like protein 3 in HoFH
- Prof. Frederick Raal